[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620976":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":36,"responsibleParty":52,"collaborators":55,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":20,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":20,"maxAge":20,"enrollmentInfo":66,"targetDuration":20,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":39,"whyStopped":20,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Chang Gung Memorial Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"single arm","EXPERIMENTAL","Participants receive 250 mL microbiota fluid delivered to the terminal ileum\u002Fcecum via ileocolonoscopy or to the duodenum via panendoscopy, with a second FMT given 7-21 days later and an optional third dose based on response.",[13],"Biological: Fecal microbiota transplantation (FMT)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","Fecal microbiota transplantation (FMT)","About 250 mL microbiota fluid, containing approximately 60 cm³ of stool materials; 6x10¹³ bacteria, will be delivered to the terminal ileum\u002Fcecum via ileocolonoscopy or to the duodenum via panendoscopy, with a second FMT given 7-21 days later and an optional third dose based on response.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Hsiao-Wen KAO, M.D.","PRINCIPAL_INVESTIGATOR",[26,32],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Hsiao-Wen Kao, M.D.","CONTACT","+886-3-3281200","2524","hsiaowen@cgmh.org.tw",{"name":33,"role":28,"phone":29,"phoneExt":34,"email":35},"Tung-Lian Lin, M.D.","2534","ldl2605@cgmh.org.tw",[37],{"facility":38,"status":39,"city":40,"state":20,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Chang Gung Memorial Hospital at Linkou","RECRUITING","Taoyuan","333423","Taiwan","TW",{"type":45,"coordinates":46},"Point",[47,48],121.29696,24.99368,{"lat":48,"lon":47},[51],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},{"type":24,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Hsiaowen Kao","M.D., Division of Hematology-Oncology",[56],{"name":57,"class":6},"National Taiwan University Hospital","100620976","phase-2-fecal-microbiota-transplantation-for-steroid-refractory-acute-gi-gvhd-100620976",false,"NCT07364617","Fecal Microbiota Transplantation for Steroid-Refractory Acute GI GVHD","Fecal Microbiota Transplantation for the Treatment of Steroid Refractory Acute Gastrointestinal Graft-Versus-Host Disease in Patients After Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n1. Stage II to IV steroid refractory acute GI-GvHD in allo-HSCT recipients\n\n   1. Stage II to IV acute GI-GVHD subjects, having \\>1000 mL stool per day, diarrhea \\> 5 times\u002Fday, or abdominal cramping, bleeding or ileus, AND\n   2. Resistant to a first-line therapy with corticosteroids (CS)\n\n   \u003C!-- -->\n\n   1. Lack of improvement after 5 days of treatment with CS at 2 mg\u002Fkg\u002Fd methylprednisolone or other CS with equivalent dose,\n   2. Progression after 3 days of treatment with CS at 2 mg\u002Fkg\u002Fd methylprednisolone or other CS with equivalent dose.\n2. Age ≥ 18 years old.\n3. Allo-HSCT with any type of donor, stem cell source, GvHD prophylaxis or conditioning regimen.\n4. Allow vancomycin-resistant enterococcus (VRE) colonization and asymptomatic cytomegalovirus (CMV) viremia, which is defined as a detectable CMV viral load in plasma but without tissue-invasive disease.\n5. Patients able to have a minimum of 12 hours discontinuation of systemic antibiotics in order to perform the allogeneic FMT (antiviral and antifungal agents are allowed)\n6. Signature of informed and written consent by the subject or by the subject's legally acceptable representative for patients under guardianship or trusteeship. Subject must understand and voluntarily sign an informed consent form prior to any study-related assessments\u002Fprocedures being conducted.\n\nExclusion Criteria:\n\n1. Absolute neutrophil count \\\u003C 500 cells\u002FuL.\n2. Absolute platelet count \\\u003C 30000 \u002FuL which is not correctable by transfusion\n3. Hemodynamically unstable status with the following conditions: systolic blood pressure \\\u003C 90 mm Hg, pulse oximeter oxygen saturation (SpO2) \\\u003C 90%, PaO2 \\\u003C 60 mm Hg, or respiratory rate \\> 22\u002Fminute.\n4. Uncontrolled and active infection from bacteria, virus, or fungus as determined by the investigators.","ALL",{"count":67,"type":68},35,"ESTIMATED","INTERVENTIONAL",[71],"PHASE2","Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for various hematologic diseases. However, one of the major challenges of allo-HSCT is the occurrence of graft-versus-host disease (GvHD), particularly acute gastrointestinal GvHD (GI-GvHD). GvHD occurs when donor T cells recognize the recipient's tissue as foreign and mount an immune attack against it. Acute GI-GvHD is a common complication following allo-HSCT and a significant cause of mortality. If the initial steroid treatment for acute GvHD fails, mortality rates can reach as high as 81%.\n\nRecent studies have shown a strong association between reduced gut microbiota diversity and high mortality in patients with acute GI-GvHD, highlighting the critical role of the gut microbiome in regulating immune responses and maintaining intestinal homeostasis. Consequently, fecal microbiota transplantation (FMT) has emerged as a potential therapeutic strategy aimed at restoring a healthy gut microbiome and improving clinical outcomes in patients with acute GI-GvHD.\n\nThis study aims to evaluate the efficacy and safety of FMT in patients with steroid-refractory or steroid-resistant acute GI-GvHD. The findings of this research will contribute to establishing FMT as a potential and effective treatment option for managing severe acute GI-GvHD, thereby improving patient outcomes and reducing transplant-related mortality.",[74],"Graft vs Host Disease",[76,77,78],"Acute Gastrointestinal Graft-versus-Host Disease","fecal microbiota transplantation","steroid-refractory","2026-05-21",{"date":81,"type":82},"2026-05-22","ACTUAL",{"date":84,"type":82},"2026-04-29",{"date":86,"type":68},"2028-02-28",{"name":5,"class":6},1]